What to do when you diagnosed with Alzheimer's and MCI

Mild Cognitive Impairment (MCI) is a condition characterized by cognitive changes that are noticeable to the individual and others but do not meet the criteria for a diagnosis of dementia. It is considered an intermediate stage between the normal cognitive decline of aging and more severe cognitive impairment seen in conditions like Alzheimer's disease.

MCI increases the risk of Alzheimer's by 400% in the next five years. Although not everyone with MCI will progress to dementia, individuals with MCI have a higher risk of developing Alzheimer's disease or other types of dementia compared to the general population. However, some people with MCI remain stable or even improve over time.

MCI can be classified into different subtypes based on the affected cognitive domain. Amnestic MCI primarily affects memory, while non-amnestic MCI involves other cognitive domains like language, attention, or executive function.

Here is 4 approach to start immediately

• Identifying contributing factors: Understanding the various contributors to cognitive decline and Alzheimer's disease, including inflammation, nutrient deficiencies, hormonal imbalances, toxins, and lifestyle factors.
• Personalized approach: Develop personalized treatment plans based on an individual's specific risk factors, genetics, and health profile. Dr. Bredesen highlights the importance of thorough testing to identify these factors and tailor interventions accordingly.
• Multi-faceted interventions: The ReCODE protocol involves multiple interventions targeting various aspects of cognitive health. These interventions can include dietary changes, optimizing sleep, stress reduction techniques, exercise, targeted supplements, and brain training exercises.
• Continuous monitoring and optimization: Start ongoing monitoring of cognitive function and biomarkers to assess progress and make necessary adjustments to the treatment plan.

Dr. Dale Bredesen's book "The End of Alzheimer's Program" is a guide that outlines his approach to preventing and reversing cognitive decline, including Alzheimer's disease. Dr. Bredesen is a neurologist and researcher known for his work on the treatment and prevention of Alzheimer's disease. The book builds upon Dr. Bredesen's previous work, including his 2017 book "The End of Alzheimer's: The First Program to Prevent and Reverse Cognitive Decline." It presents an expanded version of his protocol, known as the ReCODE (Reversal of Cognitive Decline) protocol, which aims to address the underlying causes of cognitive decline and Alzheimer's disease. Case studies: The book includes case studies of individuals who have followed the ReCODE protocol and experienced improvements in cognitive function and quality of life.